February 4, 2014
Speaking at a seminar held in Tokyo by Astellas Pharma on January 31, Takashi Kadowaki, professor at the Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, University of Tokyo, stated that glucose co-transporter-2 (SGLT-2) inhibitors, which are expected...read more